Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of ritonavir-boosted BILR 355 in NNRTI-experienced HIV-1 infection
2005-004698-39Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BILR 355 in Human immunodeficiency virus infection type 1 (3 arms), sponsored by Boehringer Ingelheim. Started Dec 2005; status: completed.
02
Drugs
BILR 355
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-004698-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004698-39.